Status:

COMPLETED

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

Lead Sponsor:

MediciNova

Conditions:

Pneumonia, Viral

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

The goal of this study is to evaluate the effects of Ibudilast (MN-166) versus placebo in hospitalized patients infected with COVID-19 at risk for developing acute respiratory distress syndrome (ARDS)...

Detailed Description

This is a randomized (1:1) double-blind, placebo-controlled, parallel-group study evaluating the efficacy of Ibudilast to prevent ARDS in hospitalized patients infected with COVID-19 who are at risk f...

Eligibility Criteria

Inclusion

  • SARS-CoV-2 infection confirmed with WHO criteria (including a positive PCR of any specimen, e.g., blood, respiratory, stool, urine, or any other body fluid)
  • Chest imaging (radiograph, computerized tomography (CT) scan or lung ultrasound) with abnormalities consistent with COVID-19 pneumonia
  • Oxygen saturation (SpO2) ≤92% on room air (RA), respiratory rate ≥24 breaths per min on RA, and/or requirement for supplemental oxygen
  • At least 1 risk factor which may put patient at higher risk for more severe illness from COVID-19: Age \> 65, underlying serious heart disease, chronic lung disease, moderate to severe asthma, body mass index of ≥40, or diabetes

Exclusion

  • Suspected active bacterial, fungal, viral, or other cause of respiratory failure other than COVID-19
  • Subject is already intubated and on ventilator support
  • Known or suspected immunosuppression with immunosuppressant medications or chemotherapeutic agents
  • Patient is receiving dialysis treatment
  • On a home ventilator support or continuous domiciliary oxygen therapy for baseline lung disease
  • Active tuberculosis infection

Key Trial Info

Start Date :

January 11 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 7 2024

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT04429555

Start Date

January 11 2021

End Date

August 7 2024

Last Update

October 30 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Denver Health and Hospital Authority

Denver, Colorado, United States, 80204

2

Yale University School of Medicine

New Haven, Connecticut, United States, 06520